Fresenius Medical Care AG & Co. KGaA 3/31/2026 Earnings Report

Fresenius Medical Care AG & Co. KGaA EPS Results

• Actual EPS: $1.05
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Fresenius Medical Care AG & Co. KGaA Revenue Results

• Actual Revenue: $5.34 billion
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Fresenius Medical Care AG & Co. KGaA Announcement Details

• Date: 3/31/2026
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines. These offerings are complemented by a range of pharmaceuticals, including anticoagulants and iron therapies, along with digital health solutions for remote patient monitoring and data management. By integrating clinical expertise with proprietary technology, Fresenius Medical Care aims to improve treatment outcomes and enhance patient quality of life.

Founded in 1996 as a spin‐off from the Fresenius SE healthcare group, Fresenius Medical Care is headquartered in Bad Homburg, Germany. The company maintains a presence in over 50 countries across North America, Europe, Latin America and the Asia Pacific region. Its global reach is supported by manufacturing facilities, research centers and a network of more than 4,000 dialysis clinics, serving hundreds of thousands of patients worldwide.